Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma

Translational Research

Volumn 166, Issue 5, 2015, Pages 412-424

  Quirk, Shannon K ^a   Shure, Anna K ^a   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TALIMOGENE LAHERPAREPVEC; TICILIMUMAB; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COLITIS; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DRUG SAFETY; EFFECTOR CELL; ENDOCRINE DISEASE; EYE DISEASE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; METASTATIC MELANOMA; NEUROLOGICAL COMPLICATION; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TOXIC HEPATITIS; COMBINATION DRUG THERAPY; IMMUNOLOGY; MELANOMA; METASTASIS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; CTLA-4 ANTIGEN; DRUG THERAPY, COMBINATION; HUMANS; MELANOMA; NEOPLASM METASTASIS;

EID: 84944281519     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.06.005     Document Type: Review

References (106)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. C. Karimkhani, R. Gonzalez, and R.P. Dellavalle A review of novel therapies for melanoma Am J Clin Dermatol 15 2014 323 337
3. O. Hamid, C. Robert, A. Daud, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144
4. E.J. Lipson, W.H. Sharfman, C.G. Drake, and et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin Cancer Res 19 2013 462 468
5. A. Ribas, F.S. Hodi, R. Kefford, and et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) J Clin Oncol 32 18 suppl 2014 [meeting abstracts] [abstract LBA9000]
6. C. Robert, A. Ribas, J.D. Wolchok, and et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 9948 2014 1109 1117
7. J.R. Brahmer, C.G. Drake, I. Wollner, and et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
8. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
9. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody inpatients with advanced cancer N Engl J Med 366 2012 2455 2465
10. R.S. Herbst, J.C. Soria, M. Kowanetz, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
11. E.J. Lipson, and C.G. Drake Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma Clin Cancer Res 17 2011 6958 6962
12. T.R. Simpson, F. Li, W. Muntalvo-Ortiz, and et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma J Exp Med 210 2013 1695 1710
13. D.B. Page, M.A. Postow, M.K. Callahan, J.P. Allison, and J.D. Wolchok Immune modulation in cancer with antibodies Annu Rev Med 65 2014 185 202
14. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 2002 12293 12297
15. J.S. Weber, S.P. D'Angelo, D. Minor, and et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open-label phase 3 trial Lancet Oncol 16 2015 375 384
16. J.M. Kirkwood, P. Lorigan, P. Hersey, and et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma Clin Cancer Res 16 2010 1042 1048
17. A. Ribas, R. Kefford, M. Marshall, and et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J Clin Oncol 31 2013 616 622
18. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
19. C. Robert, L. Thomas, I. Bondarenko, and et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
20. D. McDermott, J. Haanen, T.-T. Chen, P. Lorigan, and S. O'Day Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) Ann Oncol 24 2013 2694 2698
21. R. Ibrahim, D. Berman, V. de Pril, and et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma J Clin Oncol 29 2011 [abstract no. 8583]
22. J.S. Weber, K.C. Kähler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol 30 2012 2691 2697
23. M.E. Lacouture, J.D. Wolchok, G. Yosipovitch, and et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events J Am Acad Dermatol 71 2014 161 169
24. A. Tarhini Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management Scientifica (Cairo) 2013 2013 857519
25. O. Klein, L.M. Ebert, T. Nicholaou, and et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4 Clin Cancer Res 15 2009 2507 2513
26. R.B. Reule, and J.P. North Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab J Am Acad Dermatol 69 2013 272 273
27. W.V. Vogel, A. Guislain, P. Kvistborg, and et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission J Clin Oncol 30 2012 e7 e10
28. A. Eckert, A. Schoeffler, S. Dalle, and et al. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient Dermatology 218 2009 69 70
29. S. Wilgenhof, and B. Neyns Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient Ann Oncol 22 2011 991 993
30. C. Tissot, A. Carsin, N. Freymond, Y. Pacheco, and G. Devouassoux Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy Eur Respir J 41 2013 246 247
31. J.N. Choi Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab Semin Cutan Med Surg 33 2014 40 48
32. K.C. Kähler, and A. Hauschild Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma J Dtsch Dermatol Ges 9 2011 277 286
33. D. Berman, S.M. Parker, J. Siegel, and et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma Cancer Immun 10 2010 11
34. S. Nancey, G. Boschetti, E. Cotte, and et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis? Inflamm Bowel Dis 18 2012 E1598 E1600
35. L. Burdine, K. Lai, and J.A. Laryea Ipilimumab-induced colonic perforation J Surg Case Rep 2014 10.1093/jscr/rju010
36. K.A. Mitchell, H. Kluger, M. Sznol, and D.J. Hartman Ipilimumab-induced perforating colitis J Clin Gastroenterol 47 2013 781 785
37. S. Iwama, A. De Remigis, M.K. Callahan, and et al. Pituitary expression of CLTA-4 mediates hypophysitis secondary to administration of CLTA-4 blocking antibody Sci Transl Med 6 2014 1 11
38. M. Ryder, M. Callahan, M.A. Postow, J. Wolchok, and J.A. Fagin Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution Endocr Relat Cancer 21 2014 371 381
39. G. Borodic, D.M. Hinkle, and Y. Cia Drug-induced graves disease from CTLA-4 receptor suppression Ophthal Plast Reconstr Surg 27 2011 e87 e88
40. L. Min, and N. Ibrahim Ipilimumab-induced autoimmune adrenalitis Lancet Diabetes Endocrinol 1 2013 e15
41. K.W. Kim, N.H. Ramaiya, K.M. Krajewski, and et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings Invest New Drugs 31 2013 1071 1077
42. E. McElnea, A. Ni Mhealoid, S. Moran, and et al. Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab Orbit 22 2014 424 427
43. A.D. Henderson, and D.A. Thomas A case report of orbital inflammatory syndrome secondary to ipilimumab Ophthal Plast Reconstr Surg 31 2014 e68 e70
44. O.L. Yeh, and C.E. Francis Ipilimumab-associated bilateral optic neuropathy J Neuroophthalmol 35 2015 144 147
45. C. Lemech, and H.T. Arkenau Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities Clin Med Insights Oncol 6 2012 53 66
46. H. Izzedine, V. Gueutin, C. Gharbi, and et al. Kidney injuries related to ipilimumab Invest New Drugs 32 2014 769 773
47. S. Wilgenhof, V. Morlion, A.C. Seghers, and et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor Anticancer Res 32 2012 1355 1359
48. F. Bompaire, C. Mateus, H. Taillia, and et al. Severe meningo-radiculo-nevritis associated with ipilimumab Invest New Drugs 30 2012 2407 2410
49. J.S. Weber, A. Amin, D. Minor, and et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial Melanoma Res 21 2011 530 534
50. J.C. Yang, M. Hughes, U. Kammula, and et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunother 30 2007 825 830
51. S.J. O'Day, M. Maio, V. Chiarion-Sileni, and et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann Oncol 21 2010 1712 1717
52. M. Maur, C. Tomasello, A. Frassoldati, M.V. Dieci, E. Barbieri, and P. Conte Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma J Clin Oncol 30 2012 e76 e78
53. I. Thaipisuttikul, P. Chapman, and E.K. Avila Peripheral neuropathy associated with ipilimumab: a report of 2 cases J Immunother 38 2015 77 79
54. C.J. Voskens, S.M. Goldinger, C. Loquai, and et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network PLoS One 8 2013 e53745
55. S. Bhatia, B.R. Huber, M.P. Upton, and J.A. Thompson Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report J Immunother 32 2009 203 205
56. C. Gaudy-Marqueste, S. Monestier, J. Franques, E. Cantais, M.-A. Richard, and J.-J. Grob A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis J Immunother 36 2013 77 78
57. E.J. Gettings, C.T. Hackett, and T.F. Scott Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma Mult Scler 21 2015 670
58. B. Liao, S. Shroff, C. Kamiya-Matsuoka, and S. Tummala Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma Neuro Oncol 16 2014 589 593
59. G. Della Vittoria Scarpati, C. Fusciello, F. Perri, and et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events Onco Targets Ther 7 2014 203 209
60. L.A. Fecher, S.S. Agarwala, F.S. Hodi, and J.S. Weber Ipilimumab and its toxicities: a multidisciplinary approach Oncologist 18 2013 733 743
61. A. Fischer, A.C. Rosen, C.J. Ensslin, S. Wu, and M.E. Lacouture Pruritis to anticancer agents targeting the EGFR, BRAF, and CTLA-4 Dermatol Ther 26 2013 135 148
62. G. Tosti, E. Cocorocchio, and E. Pennacchioli Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma Clin Cosmet Investig Dermatol 6 2013 245 256
63. R. Anderson, P. Norgaard, M.K. Al-Jailawi, and I.M. Svane Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab Oncoimmunology 3 2014 e954506
64. K.P. Murphy, M.P. Kennedy, J.E. Barry, K.N. O'Regan, and D.G. Power New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonoal antibody treatment Oncol Res Treat 37 2014 351 353
65. R. Gormley, K. Wanat, R. Elenitsas, and et al. Ipilimumab-associated Sweet syndrome in a melanoma patient J Am Acad Dermatol 71 2014 e211 e213
66. R.L. Kyllo, M.K. Parker, I. Rosman, and A.C. Musiek Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma J Am Acad Dermatol 70 2014 e85 e86
67. A.S. Sheik, A.L. Goddard, J.J. Luke, and et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade JAMA Dermatol 151 2015 195 199
68. C. Ma, and A.W. Armstrong Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b and interleukin-2 J Dermatolog Treat 25 2014 401 408
69. J.L. McCutcheon, C.M. McClain, I. Puzanov, and T.A. Smith Infectious colitis associated with ipilimumab therapy Gastroenterol Res 7 2014 28 31
70. A.M. Di Giacomo, R. Danielli, M. Guidoboni, and et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases Cancer Immunol Immunother 58 2009 1297 1306
71. J.A. Blansfield, K.E. Beck, K. Tran, and et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer J Immunother 28 2005 593 598
72. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 127 133
73. A.V. Maker, J.C. Yang, R.M. Sherry, and et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma J Immunother 29 2006 455 463
74. A.T. Faje, R. Sullivan, D. Lawrence, and et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma J Clin Endocrinol Metab 99 2014 4078 4085
75. F. Albarel, C. Gaudy, F. Castinetti, and et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma Eur J Endocrinol 172 2015 195 204
76. A. Juszczak, A. Gupta, N. Karavitaki, M.R. Middleton, and A.B. Grossman Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review Eur J Endocrinol 167 2012 1 5
77. F. Torino, A. Barnabeli, L. De Vecchis, R. Salvatori, and S.M. Corsello Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease Oncologist 17 2012 525 535
78. S.M. Corsello, A. Barnabei, Paolo Marchetti, and et al. Endocrine side effects induced by immune checkpoint inhibitors J Clin Endocrinol Metab 98 2013 1361 1374
79. Y. Chodakiewitz, S. Brown, J.L. Boxermann, J.M. Brody, and J.M. Rogg Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis Clin Neurol Neurosurg 125 2014 125 130
80. A. Anderson, and V. Bhatia Ipilimumab immune-related adverse reactions: a case report S D Med 66 2013 315 317
81. L. Min, F.S. Hodi, A. Giobbie-Hurder, and et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study Clin Cancer Res 21 2015 749 755
82. G. Borodic, and D.M. Hinkle Reply Re: "Drug-induced Graves disease from CTLA-4 receptor suppression" Ophthal Plast Reconstr Surg 29 2013 241
83. S.G. Bernardo, M. Moskalenko, M. Pan, and et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma Melanoma Res 23 2013 47 54
84. K.E. Beck, J.A. Blansfield, K.Q. Tran, and et al. Entercolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J Clin Oncol 24 2006 2283 2289
85. P.M. Forde, K. Rock, G. Wilson, and K.J. O'Bryne Ipilimumab-induced immune-related renal failure - a case report Anticancer Res 32 2012 4607 4608
86. B. Thajudeen, M. Madhrira, E. Bracamonte, and L.D. Cranmer Ipilimumab granulomatous interstitial nephritis Am J Ther 22 2015 e84 e87
87. F. Fadel, K.E. Karoui, and B. Knebelmann Anti-CTLA4 antibody-induced lupus nephritis N Engl J Med 361 2009 211 212
88. E.C. Jolly, M.R. Clatworthy, C. Lawrence, P.D. Nathan, and K. Farrington Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis NDT Plus 2 2009 300 302
89. D.B. Johnson, V. Saranga-Perry, P.J. Lavin, and et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma J Clin Oncol 32 2014 1 3
90. C. Kyi, M.D. Hellmann, J.D. Wolchok, P.B. Chapman, and M.A. Postow Opportunistic infections in patients treated with immunotherapy for cancer J Immunother Cancer 2 2014 19
91. A.M. Di Giacomo, R. Danielli, L. Calabrò, and et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) Cancer Immunol Immunother 60 2011 467 477
92. J. Kopecký, P. Trojanová, O. Kubeček, and O. Kopecký Treatment possibilities of ipilimumab-induced thrombocytopenia - case study and literature review Jpn J Clin Oncol 45 2015 1 4
93. I.O. Gordon, T. Wade, K. Chin, J. Dickstein, and T.F. Gajewski Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma Cancer Immunol Immunother 58 2009 1351 1353
94. M. Akhtari, E.K. Waller, D.L. Jaye, and et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody) J Immunother 32 2009 322 324
95. E. Simeone, A.M. Grimaldi, A. Esposito, and et al. Serious haematologial toxicity during and after ipilimumab treatment: a case series J Med Case Rep 8 2014 240
96. J. Delyon, C. Mateus, and T. Lambert Hemophilia A induced by ipilimumab N Engl J Med 365 2011 1747 1748
97. P. Attia, G.Q. Phan, A.V. Maker, and et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 2005 6043 6053
98. J. Broucek, T. Hughes, E. Huelsmann, and et al. Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment J Immunother Cancer 2 suppl 3 2014 97
99. F.S. Hodi, S. Lee, D.F. McDermott, and et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial JAMA 312 2014 1744 1753
100. R.H.I. Andtbacka, F.A. Collichio, T. Amatruda, and et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-Vec) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma J Clin Oncol 31 2013 [suppl abstract LBA9008]
101. I. Puzanov, M.M. Milhem, R.H.I. Andtbacka, and et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (IPI) in previously untreated, unresected stage IIIB-IV melanoma J Clin Oncol 32 2014 [suppl abstract9029]
102. J. Yuan, M. Adamow, B.A. Ginsberg, and et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab Proc Natl Acad Sci U S A 108 2011 16723 16728
103. S. Kelderman, B. Heemskerk, H. van Tinteren, and et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma Cancer Immunol Immunother 63 2014 449 458
104. P. Queirolo, A. Morabito, S. Laurent, and et al. Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study Cancer Invest 31 2013 336 345
105. D.B. Johnson, C.M. Lovly, M. Flavin, and et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies Cancer Immunol Res 3 2015 288 295
106. A. Snyder, V. Makarov, T. Merghoub, and et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 371 2014 2189 2199